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1. Introduction  
Myocarditis is a clinical syndrome characterized by inflammation of myocardium. It can be 
produced by a myriad of etiologies including infectious, autoimmune, myocardial toxins, 
hypersensitivity reactions and physical agents. Virtually any infectious agent can produce 
myocardial inflammation and injury. Human myocarditis is most frequently caused by viral 
infection. Ongoing viral infection, myocardial destruction, and adverse remodeling can lead 
to persistent ventricular dysfunction and dilated cardiomyopathy. The modern molecular 
techniques have facilitated new insights into inflammatory autoimmune processes that 
affect the myocardium and ultimately result in acute or chronic dilated cardiomyopathy. 
The clinical manifestations are highly variable, ranging from asymptomatic 
electrocardiographic or echocardiographic abnormalities to acute myocardial infarction-like 
syndrome, overt congestive heart failure, fulminant condition with new atrial or ventricular 
arrhythmias or profound cardiogenic shock and death. Myocarditis is occasionally the 
unrecognized culprit in cases of sudden cardiac death. Autopsy series have reported much 
higher rates of myocarditis than expected with overt clinical manifestation from different 
etiological agents. The prospective postmortem data have implicated myocarditis in sudden 
cardiac death of young adults at rates of 8.6 percent to 12 percent (Doolan et al., 2004; Fabre 
& Sheppard, 2005). Furthermore, it has been identified as a cause of dilated cardiomyopathy 
in 9 percent of cases in a large prospective series (Felker et al., 1999). 
The clinical history in patients presented with myocarditis remains essential to envelop a 
wide variety of etiologies in the clinical scenarios, many of which are infectious (Brodison & 
Swann, 1998). In the past 10 years, however, viruses, including adenovirus, parvovirus B19, 
hepatitis C, and herpes virus 6, have emerged as significant pathogens (Mahrholdt et al., 
2006). The geographical distribution can be of relevance for some forms of myocarditis. In 
selected countries, Chagas disease, Lyme myocarditis, acute rheumatic fever and disorders 
associated with advanced human immune deficiency virus infection are significant causes. 
Other important infrequent clinicopathologic variants in the etiological spectrum are 
systemic disorders like giant cell myocarditis, cardiac sarcoidosis and eosinophilic 
myocarditis. Additionally, drugs, vaccinations, toxins, physical agents like radiation, heat 
stroke and hypothermia can be the key point for some rare clinical diagnoses. The physical 
examination in patients with myocarditis might be normal, but more severe cases frequently 
evident for significant physical findings. Although histological findings remains the gold 
standard for establishing the diagnosis of myocarditis, low risk patients are often given a 
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presumptive diagnosis if imaging studies and a compatible clinical scenario suggest new 
onset cardiomyopathy. The clinical manifestations of suspected patients with myocarditis 
will be discussed in details.  
2. Clinicopathological classification 
Over the past two decades, a great deal of confusion may be traced to the changing 
diagnostic criteria, multifaceted classifications, and varying patterns of infectious disease. 
The details of classifications will be discussed in other chapter in this book.  
The morphologic criteria for the diagnosis of myocarditis by means of endomyocardial 
biopsy interpretation was proposed by the Dallas criteria authors in 1986 who defined 
myocarditis as a process characterized by the presence of an inflammatory cell infiltration of 
the myocardium with necrosis and/or degeneration of myocytes that is not typical of the 
myocardial damage of ischemic heart disease. The inflammatory cells are typically 
lymphocytic but may also include eosinophilic, neutrophilic, giant cells, granulomatous, or 
mixed cellularity infiltration. The amount of inflammation and its distribution may be mild, 
moderate, or severe and focal, confluent, or diffuse, respectively. A retrospective study of 
112 consecutive patients with biopsy-confirmed myocarditis demonstrated, 55 percent 
lymphocytic; 22 percent borderline (inflammatory cellular infiltrate with no evidence of 
myocyte necrosis); 10 percent granulomatous; 6 percent giant cell and 6 percent eosinophilic 
form of myocarditis (Magnani et al., 2006). The viral etiology of myocarditis is thought to be 
the primary causative agents in most cases. However, a direct causative relationship still less 
well established in many clinical occasions. The majority of these cases are classified as 
lymphocytic myocarditis.  
The Dallas criteria considered to be the first attempt to develop standardized 
histopathological description of biopsy samples from patients presented with myocarditis 
(Aretz et al., 1987). However, the histopathology alone can be inadequate to identify the 
presence of active myocarditis. Some clinicians feel that the definition is too narrow owing 
to the limitation by variable interpretation, lack of clinical prognostic values, and low 
sensitivity (Baughman, 2006). A combination of histopathologic characteristics and clinical 
criteria has been proposed in 1991 (Lieberman et al., 1991) as an alternative scheme to be 
utilized in the diagnosis of myocarditis. Histologic evidence of myocarditis was 
demonstrated in 35 of 348 patients submitted to endomyocardial biopsy over 5 years. 
Analysis of the histologic findings and clinical course of these patients resulted in a 
clinicopathologic classification of myocarditis in which four clinical subgroups are 
identified.  
2.1 Fulminant myocarditis 
The fulminant myocarditis is less frequent form of presentation. Patients presents with acute 
heart failure and cardiogenic shock up to two weeks after a distinct viral prodrome. They 
have severe cardiovascular compromise and may require mechanical circulatory support. 
Multiple foci of active myocarditis are typical. The histopathologic finding does not match 
the clinical phenotypic severity. The ventricular dysfunction often normalizes if patients 
survive the acute illness or results in death (McCarthy et al., 2000). In one series, 14 of 147 
patients (10.2 percent) with clinical myocarditis presented in a fulminant fashion, with the 
triad of hemodynamic compromise, rapid onset of symptoms (usually within 2 weeks), and 
fever (McCarthy et al., 2000). On follow up, 93 percent of the original cohorts were alive and 
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transplant free 11 years following initial biopsy, compared with only 45 percent in those 
with more classic forms of acute myocarditis.  
2.2 Acute myocarditis  
Classically, patients with acute myocarditis presents with a less distinct onset of illness with 
nonspecific symptoms related to the heart. Viral prodrome occurs between 20 and 80 
percent of the cases, can be readily missed by the patient, and thus cannot be relied upon for 
diagnosis. They present with an established ventricular dysfunction and may respond to 
immunosuppressive therapy or their condition may progress to dilated cardiomyopathy. In 
a series of 245 patients with clinically suspected myocarditis, the most common symptoms 
include fatigue (82 percent); dyspnea on exertion (81 percent); arrhythmias (55 percent, both 
supraventricular and ventricular); palpitations (49 percent); and chest pain at rest (26 
percent), (Kuhl et al., 2005). The presentation can mimic acute coronary syndromes in view 
of troponin release, ST segment elevation on electrocardiogram, and segmental wall motion 
abnormalities on echocardiogram.  
2.3 Chronic active myocarditis 
This group of patients with chronic active myocarditis represents the majority of older adult 
with myocarditis. They are also presents with a less distinct onset of illness and often 
insidious with symptoms compatible with moderate ventricular dysfunction such as fatigue 
and dyspnea. Affected patients may initially respond to immunosuppressive therapy but 
often have clinical and histologic relapses and develop ventricular dysfunction associated 
with chronic inflammatory changes, and mild to moderate fibrosis on histological study 
including giant cells. 
2.4 Chronic persistent myocarditis  
This group of patients with chronic persistent myocarditis, whom also presents with a less 
distinct onset of illness, is characterized by a persistent histological infiltrate, often with foci 
of myocyte necrosis but without ventricular dysfunction, despite other cardiovascular 
symptoms such as chest pain or palpitation. 
The previously depicted four forms are still used to describe the clinical presentation and 
progression of myocarditis, particularly in the absence of ongoing histological evaluation. 
These categories may also provide some prognostic information and may suggest which 
patients can or cannot benefit from immunosuppressive therapy. 
A new diagnostic criteria derived from limited data was proposed in 2009. The Lake Louise 
Consensus Criteria utilizes the cardiac magnetic resonance imaging (CMR) for the diagnosis 
of myocarditis (Friedrich et al., 2009). The CMR enhances the ability to detect myocardial 
inflammation through noninvasive means, as well as to improve diagnostic accuracy. In 
these criteria, four major domains are considered when making the diagnosis including,  
clinical presentation compatible with myocarditis, evidence of new or recent onset 
myocardial damage, increased T2 signal or delayed enhancement on CMR (compatible with 
myocardial edema and inflammation), and endomyocardial biopsy evidence of myocardial 
inflammation. The use of CMR appears suitable to identify patients with significant ongoing 
inflammation, which may be especially important for patients with recurrent or persisting 
symptoms and in patients with new onset heart failure. The awareness came out that the 
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recommendations proposed by these criteria are based on limited data and that not all 
centers will be able to apply all components of the suggested protocol.  
3. Clinical manifestation 
Myocarditis is synonymous with inflammatory cardiomyopathy which has a wide range of 
clinical presentation, from subtle to devastating clinical scenario that contributes to the 
difficulties in diagnosis and classification of this disorder. There are few population-based, 
epidemiologic studies which have defined the presenting symptoms of acute myocarditis; 
this is due to the absence of a safe and sensitive noninvasive test that can confirm the 
diagnosis. Worldwide, the true frequency of disease in its less severe forms, whether clinical 
or subclinical, across various age segments of the population are more difficult to 
appreciate. Table 1 summarized the most significant clinical manifestations and physical 
findings in patients presented with myocarditis. Typically myocarditis has a bimodal age 
distribution in the general population, with the acute presentation more commonly seen in 
young children and teenagers. In contrast, the presenting symptoms are more subtle and 
insidious, often with dilated cardiomyopathy and heart failure in the older adult 
population. Most studies of acute myocarditis reported a slight preponderance in male 
patients (Caforio et al., 2007). The male-to-female ratio is 1.5 to 1, which may be related to a 
protective effect of natural hormone variations on immune responses in women (Schwartz 
et al., 2004). The variable clinical manifestation of myocarditis in part reflects the variability 
in histological disease severity. Myocardial inflammation may be focal or diffuse, involving 
any or all cardiac chambers. Severe, diffuse myocarditis can result in a clinical manifestation 
of acute dilated cardiomyopathy.  
Many patients with myocarditis present with a nonspecific illness characterized by fatigue, 
mild dyspnea, and myalgias. Most cases of viral myocarditis are subclinical; therefore, the 
patient infrequently seeks medical attention during acute illness. These subclinical cases 
may have transient electrocardiographic abnormalities. The reported antecedent infectious 
viral syndrome is highly variable, ranging from 10 percent to 80 percent of patients with 
viral myocarditis (Baboonian & Treasure, 1997; Feldman & McNamara, 2000; Imazio et al., 
2008; Mason et al., 1995). The appearance of cardiac specific symptoms occurs primarily in 
the subacute virus clearing phase; therefore, patients commonly present two weeks after the 
acute viremia. 
A few patients present acutely with fulminant congestive heart failure secondary to 
widespread myocardial involvement. Animal models have lead to a much greater 
understanding of the fulminant clinical course of myocarditis in which a rapid progression, 
severe ventricular dysfunction and cardiovascular collapse occurs (Ellis & Di Salvo, 2007). 
Fulminant myocarditis, manifested by severe hemodynamic compromise requiring high 
dose vasopressor support or mechanical circulatory support, was identified in 15 of 147 
patients (10.2 percent) in a large prospective study (McCarthy et al., 2000). Fulminant cases 
were additionally characterized by a distinct viral prodrome, fever, and abrupt onset 
(generally <3 days) of advanced heart failure symptoms. These patients typically have 
severe global left ventricular dysfunction and minimally increased left ventricular end-
diastolic dimensions. Of note, either borderline or active lymphocytic myocarditis can 
produce this dramatic clinical presentation. The histological features of chronic myocarditis 
are usually produced a more subtle clinical course. Adults may present with heart failure 
years after initial index event of myocarditis.   
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Table 1. The most significant clinical manifestations and physical findings in patient with 
myocarditis 
The medical history may embrace a number of hints that merits an emphasis. Previous 
history of rheumatic heart disease or symptoms defined by Jones criteria e.g. fever or 
arthralgia can be a clue for the clinical diagnosis acute rheumatic fever. History of tick bite 
may correlate with suspected Lyme disease. Patients treated for neoplastic disorders with 
chemotherapeutic agents like doxorubicin may draw attention to anthracyclines-induced 
myocarditis. History of travel to Central or South America can be a clue for the diagnosis of 
Chagas disease. Additionally, giant-cell myocarditis should be considered in patients with 
acute dilated cardiomyopathy associated with thymoma, autoimmune disorders, ventricular 
tachycardia, or high-grade heart block. Furthermore, an unusual cause of myocarditis, such 
as cardiac sarcoidosis, should be suspected in patients who present with chronic heart 
       Clinical manifestations 
1. Subclinical presentation (most cases of viral myocarditis) 
2. Nonspecific symptoms (e.g fatigue, arthralgias and myalgias) 
3. Clinical presentation, including : 
Shortness of breath, orthopnea or paroxysmal nocturnal 
dyspnea 
Pedal edema   
Chest pain (concomitant pericarditis) 
Palpitation (arrhythmias) 
Presyncope or syncope (atrioventricular block) 
Sudden cardiac death (dysrhythmic death) 
Fever 
Flu-like syndrome (e.g pharyngitis or tonsillitis) 
Thromboembolic symptoms (systemic or pulmonary) 
 
       Physical findings 
1. Normal or unremarkable findings 
2. Relevant physical signs, including : 
Tachypnea 
Cyanosis 
Elevated jugular venous pressure 
Tachycardia 
Signs of cardiovascular collapse and shock 
Diffuse apex beat and laterally displaced (cardiomegaly) 
Diminished intensity of first heart sound 
Third and fourth heart sound summation gallops 
Murmurs of mitral or tricuspid valves regurgitation 
Pericardial friction rub and effusion  
(concomitant myopericarditis) 
Bibasilar crackles 
Hepatomegaly 
Ascites 
Peripheral edema 
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failure, dilated cardiomyopathy and new ventricular arrhythmias, or second-degree or third 
degree heart block or who do not have a response to standard care (Yazaki et al., 1998). 
In the European Study of the Epidemiology and Treatment of Inflammatory Heart Disease, 
a 3055 patients with suspected acute or chronic myocarditis were screened, of them 72 
percent had dyspnea, 32 percent had chest pain, and 18 percent had arrhythmias (Hufnagel 
et al., 2000). The most important clinical manifestations in patients with myocarditis are as 
followed: 
3.1 Shortness of breath   
Dyspnea on exertion and fatigue are common. A history of shortness of breath at rest, 
orthopnea, pedal edema or paroxysmal nocturnal dyspnea is suggestive of congestive heart 
failure. Dyspnea is due to left ventricular dysfunction causes elevated left ventricular 
diastolic pressure and low cardiac output. 
3.2 Chest pain 
Chest pain is usually associated with concomitant pericarditis. Chest discomfort is reported 
in one third of patients. The pain is most commonly described as a pleuritic, sharp, stabbing 
precordial pain. It may be substernal and squeezing and, therefore, difficult to distinguish 
from that typical of ischemic pain. However, myocarditis can be masquerading as an acute 
coronary syndrome both clinically and on the electrocardiogram, particularly in younger 
patients (Angelini et al., 2000). In one series of 34 patients with known normal coronary 
anatomy presenting with symptoms and electrocardiographic changes consistent with an 
acute coronary syndrome, 11 (32 percent) of the patients were found to have myocarditis on 
biopsy (Dec et al., 1992).  Sarda et al., using myocardial indium111-labeled antimyosin 
antibody and rest thallium imaging, identified 35 of 45 patients (78 percent) who presented 
with acute chest pain, ischemic electrocardiographic abnormalities, and elevated cardiac 
biomarkers as having diffuse or focal myocarditis. However biopsy verification of actual 
myocarditis was not undertaken in this series. Complete recovery of left ventricular function 
occurred at six months in 81 percent of these patients (Sarda et al., 2001). Some presentations 
of myocarditis, especially those related to parvovirus B19, present like an acute lateral wall 
myocardial infarction. The ischemia associated with myocarditis may be due to localized 
inflammation or occasionally, due to coronary artery spasm (McCully et al,. 2005). It is 
essential for clinicians to consider acute myocarditis in younger patients who present with 
acute coronary syndromes when coronary risk factors are absent, electrocardiographic 
abnormalities extend beyond a single coronary artery territory or global rather than 
segmental left ventricular dysfunction is evident on echocardiography. 
3.3 Palpitation, presyncope or syncope 
Palpitation is a common presentation in patient with myocarditis. Presyncope or syncope in 
a patient with a presentation consistent with myocarditis may be a signal for high-grade 
atrioventricular block and risk for sudden death. Small focal inflammation in electrically 
sensitive areas may be the etiology of patients whose initial presentation is sudden death. 
3.4 Fever 
Fever with or without sweats and chills occur in 20 percent of patients presenting with 
myocarditis. A history of fever or flu-like syndrome in form of pharyngitis, tonsillitis, or 
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upper respiratory tract infection before admission occurs in 50 percent of patients (Imazio et 
al., 2008). 
3.5 Other symptoms   
Apart from the nonspecific symptoms recognized like malaise, myalgias and arthralgias, 
other extracardiac symptoms may identify infectious, toxic agents or autoimmune diseases 
affecting the heart and resulting in a myocarditis. A viral prodrome of fever, myalgias, and 
muscle tenderness may precede viral myocarditis, while a delayed hypersensitivity reaction 
may be first apparent from a cutaneous rash. Rash, fever, peripheral eosinophilia, or a 
temporal relation with recently initiated medications or the use of multiple medications 
suggest a possibility of hypersensitivity myocarditis.  
The clinical diagnosis of myocarditis is challenging due to its varying presentation, 
nonspecific symptoms and physical findings. Accordingly, a high level of clinical suspicion 
is warranted and a presumptive diagnosis usually made based on patient demographics and 
the clinical course. 
4. Physical examination 
The physical examination of patient presented with myocarditis is frequently normal. Mild 
cases of patients with myocarditis may appear to have a simple viral syndrome. More 
acutely ill patients with acute myocarditis have the classic signs of circulatory impairment 
due to congestive heart failure. Patients may shows signs of fluid overload including 
elevated jugular venous pressure, bibasilar crackles, hepatomegaly, ascites and peripheral 
edema. More severe cases may show cardiovascular collapse and signs of shock. In addition 
to the signs of fluid overload, the physical examination may reveal direct evidence of 
cardiovascular signs in symptomatic patients. Tachypnea and tachycardia are common. 
Tachycardia is often out of proportion to fever. Cyanosis may occur as well. The apex beat 
may be diffuse and laterally displaced suggesting cardiomegaly. Heart auscultation may 
reveal diminished intensity of first heart sound. The third and occasionally fourth heart 
sound summation gallops may be noted with impaired ventricular function, particularly 
when biventricular acute myocardial involvement results in systemic and pulmonary 
congestion. If the right or left ventricular dilatation is severe, auscultation may reveal 
murmurs of mitral or tricuspid valves regurgitation. Table 1 summarized the most 
significant clinical manifestations and physical findings in patients presented with 
myocarditis.  
A pericardial friction rub and effusion may become evident in some patients with diffuse 
inflammation as a result of myopericarditis. Pericardial tamponade was reported in very 
rare occasions. Pleural friction rub may develop as the inflammatory process involves 
surrounding structures. In cases where a dilated cardiomyopathy has developed, signs of 
peripheral or pulmonary thromboembolism may be encountered. Certain physical findings 
may imply a specific cause of myocarditis. Enlarged lymph nodes might suggest systemic 
sarcoidosis. A pruritic, maculopapular rash may suggest a hypersensitivity reaction, often to 
a drug or toxin. Acute rheumatic fever can present with the modified Jones criteria. 
5. Electrocardiogram findings 
Generally, the Electrocardiogram (ECG) is a sensitive means in myocarditis. However, its 
diagnostic value is limited by the low specificity and a wide diversity of changes which 
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observed during the course of disease. The ECG must be timely repeated, since minor 
abnormalities detected initially may become subsequently more apparent.  
The ECG findings associated with myocarditis may include first, second or third degree 
atrioventricular block, intraventricular conduction delay (widened QRS complex), bundle 
branch or fascicle block, reduced R wave height, abnormal Q waves, ST-T segment changes 
or low voltage. In one report, either ST-segment elevation or T-wave inversion is present as 
the most sensitive ECG criterion in <50% of patients, even during the first weeks of the 
disease (Morgera et al., 1992). A gradual increase in the width of the QRS complex may be a 
sign of exacerbation of myocarditis. Frequent premature beats, supraventricular tachycardia 
and atrial fibrillation may arise as well. Arrhythmias such as sinus arrest, ventricular 
tachycardia, ventricular fibrillation or asystole may occur and threaten the life of patients 
with myocarditis. Hence, continuous ECG monitoring is crucial to detect potentially fatal 
arrhythmias. 
6. Clinical manifestation of complications 
Despite the fact that a substantial number of myocarditis are never coming to medical 
attention, a less frequent form of myocarditis is fulminant and leads rapidly to 
cardiovascular collapse and shock that required mechanical ventilation support. In 
contradiction, if these patients survive the first 3-4 weeks of illness they have almost 
complete recovery and far fewer long term complications compared with those patients 
with more indolent courses (Chau et al., 2006; Khabbaz et al., 2007). Generally, there are a 
number of well recognized complications that may encounter in the variety of clinical 
scenarios of patients with myocarditis.  
6.1 Congestive heart failure  
In many patients who develop heart failure, fatigue and decreased exercise capacity are the 
initial manifestations. However, diffuse, severe myocarditis, if rapid in evolution, can result 
in acute myocardial failure and cardiogenic shock. Signs of right ventricular failure include 
increased jugular venous pressure, hepatomegaly, and peripheral edema may supervene. 
The decline in right ventricular function "protects" the left side of the circulation so that 
signs of left ventricular failure may not be seen. If, however, there is predominant left 
ventricular involvement, the patient may present with the symptoms of pulmonary 
congestion including dyspnea, orthopnea, pulmonary crackles, and, in severe cases, acute 
pulmonary edema. Patients with persistent viral genome expression show limited recovery 
of left ventricular function, decreased stroke volume index and more stiffness of the 
ventricle with the resultant long-term morbidity of heart failure and a mortality of nearly 25 
percent (Fuse et al., 2000). 
6.2 Arrhythmias 
A number of arrhythmias may be seen during the clinical course of myocarditis. Sinus 
tachycardia is more frequent than serious atrial or ventricular arrhythmias, while 
palpitations secondary to premature atrial or, more often, ventricular premature complexes 
are common. Ventricular arrhythmias and variable heart blocks are uncommon, but well 
recognized clinical presentations (Hosenpud et al., 1986; Marboe & Fenoglio et al., 1988). 
Persistent complex ventricular arrhythmias after apparent resolution of myocarditis were 
reported in children and young adults as well (Friedman et al., 1994).  
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Several series have examined the frequency of myocarditis among patients evaluated for life 
threatening ventricular arrhythmias that occurred in the absence of structural heart disease 
(Strain et al., 1983; Sugrue et al., 1984; Vignola et al., 1984). These patients tended to be 
young (younger than 50 years) and to have normal or near-normal left ventricular systolic 
function. The frequency of syncope or cardiac arrest as reported has ranged from 8 percent 
to 61 percent (Strain et al., 1983; Sugrue et al., 1984). Biopsy evidence of myocarditis among 
patients without structural heart disease has ranged from 8 percent to 50 percent. On the 
other hand, patients with ventricular arrhythmias due to lymphocytic or granulomatous 
myocarditis stay at higher risk. Sustained ventricular tachycardia or new heart block in the 
setting of rapidly progressive congestive heart failure suggests giant cell myocarditis. 
Granulomatous myocarditis has been associated more frequently with life threatening 
ventricular arrhythmias, syncope, and high-grade atrioventricular block requiring 
temporary or permanent ventricular pacing than has lymphocytic myocarditis (Davidoff et 
al., 1991; Fleming & Bailey, 1981; Sekiguchi et al., 1996). Furthermore, granulomatous 
myocarditis might be suspected in patients who present with apparently chronic dilated 
cardiomyopathy yet with new ventricular arrhythmias or heart block or who do not have a 
response to optimal care (Yazaki et al., 1998). 
6.3 Sudden cardiac death 
The risk of sudden dysrhythmic death in patients with myocarditis is increasingly 
appreciated in the current morbidity and mortality data. The discovery of myocarditis in 1 
to 9 percent of routine postmortem examinations suggests that myocarditis is a major cause 
of sudden, unexpected death (Feldman & McNamara, 2000). 
Although heart failure and cardiomyopathy are more common clinical presentations, 
patients with myocarditis may present with syncope or unexpected sudden cardiac death, 
presumably due to ventricular tachycardia or fibrillation (Drory et al., 1991; Eckart et al., 
2004; Maron et al., 2003; Theleman et al., 2001). Myocarditis is a significant cause of sudden, 
unexpected death in adults younger than age 40 years and elite young athletes. In these 
presumably healthy individuals, autopsy findings have revealed myocarditis in up to 20 
percent of cases (Wesslen et al., 1996). In an autopsy series of patients under age 40 who 
presented with sudden death in the absence of known heart disease, myocarditis was 
responsible for 22 percent of cases under age 30 and 11 percent in older subjects (Drory et 
al., 1991). In another autopsy study of sudden death occurring in 1866competitive athletes, 
myocarditis was present in 6 percent of the cardiovascular deaths (Maron et al., 2009). In one 
more series of autopsies in military recruits, myocarditis accounted for 20 percent of deaths 
due to identifiable structural cardiac abnormalities (Eckart et al., 2004). 
6.4 Dilated cardiomyopathy 
A substantial subset of symptomatic cases of postviral or lymphocytic myocarditis present 
with a syndrome of heart failure and dilated cardiomyopathy. A clinical and pathologic 
syndrome that is similar to dilated cardiomyopathy (DCM) may develop after resolution of 
viral myocarditis in animal models and biopsy proven myocarditis in human subjects 
(Gilbert & Mason, 1987). This has led to speculation that DCM may develop in some 
individuals as a result of subclinical viral myocarditis. Theoretically, an episode of 
myocarditis could initiate a variety of autoimmune reactions that injure the myocardium 
and ultimately result in the development of DCM. These abnormalities in immune 
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regulation and the variety of antimyocardial antibodies present in DCM are consistent with 
this hypothesis. Enteroviral RNA sequences may be found in heart biopsy samples in DCM 
but with a very variable frequency (0–30 percent), (Bowles et al., 1986; Giacca et al., 1994). 
Furthermore, analysis of human viruses other than enteroviruses suggests that 
adenoviruses, herpes, and cytomegalovirus can also cause myocarditis and potentially 
DCM, particularly in children and young subjects (Martin et al., 1994; Pauschinger et al., 
1999). 
In most acute cases of lymphocytic myocarditis, left ventricular function improves over one 
to six months with standard heart failure care. However a substantial minority will develop 
a persistent inflammation that leads to chronic cardiomyopathy. In the patients who 
develop chronic cardiomyopathy, the risk of heart transplantation and death is high. In a 
large review of 1230 cases of initially unexplained cardiomyopathy, 9 percent were thought 
to be due to myocarditis (Felker et al., 2000). A similar prevalence of 10 percent was noted in 
the Myocarditis Treatment Trial in which endomyocardial biopsy was performed in over 
2200 patients with unexplained heart failure of less than two years duration (Mason et al., 
1995).  
6.5 Thromboembolism 
Thromboembolism, arterial and venous, is more evident in patients with left ventricular 
dysfunction, and appears to be quite frequent complication in certain forms of myocarditis 
and cardiomyopathies. Additionally, the risk of thromboembolism from either tissue or 
thrombus from the biopsy site is higher in left ventricular biopsy. Right-sided 
thromboembolism can be due to thrombus from the venous access sheath especially with 
the internal jugular approach. The possibility of some small added diagnostic yield by 
taking biopsy samples of the left ventricle in addition to the right is outweighed by the small 
attendant risk of systemic embolism.  
Thromboembolism is frequent in advanced Chagas disease, and its occurrence is probably 
underestimated (Bestetti, 2000; Samuel et al., 1983). At autopsy, 73 percent of patients have 
left or right ventricular mural thrombi, with evidence of pulmonary or systemic 
embolization in 60 percent (Arteaga-Fernandez et al., 1989). The apical aneurysm typical of 
Chagas disease is particularly prone to the formation of thrombi and is associated with a 
high incidence of thromboembolic events (Fernandes et al., 1987). Furthermore, there is a 
high incidence of thromboembolism in population with peripartum cardiomyopathy. 
Thrombi are the result of the hypercoagulable state of pregnancy and of stasis and turbulent 
flow in the dilated heart. Thrombi often form in patients with lower left ventricular ejection 
fraction (<35 percent), (Amos et al., 2006; Sliwa et al., 2006). Higher mortality rates have 
been reported to be due to thromboembolism as well (Ford et al., 2000). 
6.6 Recurrent myocarditis 
The clinical course of myocarditis in the majority of patients is self-limited and there is 
complete resolution of myocardial inflammation without further relapse or sequelae. 
However, the disease has been observed to recur in a similar scenario to initial presentation, 
which then may resolve spontaneously or be associated with heart failure, arrhythmias, or 
death. Chronic myocarditis may be considered to be one of the mechanisms of the process of 
recurrence. Recurrence was reported to in 10 to 25 percent of patients after apparent 
resolution of the initial illness (Daly et al., 1984; Dec et al., 1985). Recurrence of myocarditis 
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is well recognized in patients with acute rheumatic fever. It is also demonstrated in 
subsequent pregnancies after peripartum cardiomyopathy and recurrence should be 
suspected if ventricular function subsequently deteriorates (Dec et al., 1985). Women should 
be counseled to avoid pregnancy after a diagnosis of peripartum cardiomyopathy. 
Recurrence was also described in giant cell myocarditis in transplanted heart which 
responded to intensive immunosuppression. History of third time recurrences of active 
myocarditis proven by endomyocardial biopsy associated with complete atrioventricular 
block was described as well and viral studies showed no evidence of recent infection 
(Kanazawa et al., 2004). Another report present recurrent viral myocarditis and vaccine-
associated myocarditis in a single patient with complete reversal of the cardiomyopathy and 
return to normal cardiac function (Makaryus et al., 2006). Moreover, some cases were 
observed to have recurrent myocarditis after tapering of immunosuppressive therapy and 
previous biopsy specimens showing healed myocarditis.  
One report indicated that pericarditis on initial presentation may be associated with a higher 
rate of recurrence of myocarditis (Fowler et al., 1973). However, in reality, there are no 
reliable predictors that identify patients likely to have recurrence.  
7. Manifestations of specific forms of myocarditis  
Specific clinical forms of myocarditis of variable etiologies will be described below. Table 2 
summarized some key clinical hints among specific forms of myocarditis that help with the 
clinical diagnosis 
7.1 Viral myocarditis 
Amongst the multiple infectious etiologies which have been implicated as the cause of 
clinically significant acute myocarditis, viral myocarditis being the most common and  the 
enterovirus coxsackie B being the most significant. Numerous seroepidemiologic and 
molecular studies were linked coxsackievirus B to outbreaks of myocarditis occurred before 
the 1990s. The spectrum of viruses that were detected in endomyocardial biopsy samples 
shifted from coxsackievirus B to adenovirus in the late 1990s. In the last decade a number of 
reports implicate new viruses in the etiology of myocarditis and dilated cardiomyopathy. 
The parvovirus B19 was identified in patients with myocarditis in Germany (Kühl et al., 
2005; Mahrholdt et al., 2006) and hepatitis C virus was reported in Japan (Matsumori 2005, 
2006) as well. 
Early studies suggested that cardiac involvement occurred in 3.5 to 5 percent of patients 
during outbreaks of coxsackievirus infection (Gerzen et al., 1972; Grist & Bell, 1969). Most 
cases of enteroviral myocarditis or pericarditis occur in children and young adults in whom 
more than two-thirds are male. In the majority of patients, active myocarditis remains 
unsuspected because the subclinical and self-limited pattern of presentation or the presence 
of myocarditis may infer only by the finding of transient electrocardiographic ST-T-wave 
abnormalities. In addition, subtle cardiac symptoms and signs may be overshadowed by the 
systemic manifestations of the underlying infection or disease process. Clinically, the 
patients give a history of a preceding upper respiratory febrile illness or a flu-like syndrome, 
and viral nasopharyngitis or tonsillitis may be evident. In the United States Myocarditis 
Treatment Trial, 89 percent of subjects reported a syndrome consistent with a viral 
prodrome (Mason et al., 1995). The patient may also have fever, myalgias, and muscle 
tenderness that is followed by chest pain, dyspnea or arrhythmias, and occasionally heart 
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failure. A pericardial friction rub is documented in half of cases, and the electrocardiogram 
shows ST segment elevations or ST- and T-wave abnormalities. Most adults recover 
completely and only a minority of cases progress to chronic dilated cardiomyopathy. 
 
Clinical clues Clinical diagnosis Comments 
Preceding upper respiratory febrile or flu-
like illness (viral nasopharyngitis  
or tonsillitis) 
Viral myocarditis Often self-limited 
Patients present with chronic heart failure, 
dilated cardiomyopathy and new 
arrhythmias or heart block with no response 
to standard care 
Sarcoid 
myocarditis 
Enlarged lymph 
nodes suggest 
systemic sarcoidosis 
Cutaneous rash (pruritic, maculopapular), 
fever, peripheral eosinophilia or a temporal 
relation with recently initiated medications 
or the use of multiple medications  
Hypersensitive/ 
eosinophilic 
myocarditis 
 
Patients treated anti-neoplastic 
chemotherapeutic agents  
Anthracyclines-
induced 
myocarditis 
 
History of travel to Central or South 
America, Systemic or pulmonary 
thromboembolism 
Chagas disease  
The apical aneurysm 
is typical in 
advanced disease 
History of residence or travel through the 
endemic area; previous tick bites; prior or 
current erythema migrans lesions and 
coexistence of neurologic dysfunction  
Lyme disease 
Varying degrees of 
atrioventricular 
conduction block is 
common  
Previous history of rheumatic heart disease 
or symptoms defined by Jones criteria e.g. 
erythema marginatum, polyarthralgia, 
chorea, subcutaneous nodules fever or 
arthralgia 
Acute rheumatic 
fever 
 
Heart failure developing in the last month 
of pregnancy or within 5 months following 
delivery 
Peripartum 
cardiomyopathy 
Higher incidence of 
thromboembolism 
(hypercoagulable 
state of pregnancy). 
More often when left 
ventricular ejection 
fraction <35 % 
Sustained ventricular tachycardia in rapidly 
progressive heart failure associated with 
thymoma, autoimmune disorders, or high-
grade heart block  
Giant-cell 
myocarditis  
Syncope or sudden 
death develop due 
to ventricular 
arrhythmias or heart  
block 
Table 2. Some key clinical hints among specific forms of myocarditis that help with the 
clinical diagnosis. 
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In addition to the coxsackievirus B, other members of the genus Enterovirus (coxsackievirus 
A, echovirus, and poliovirus) and many other viruses have also been associated less 
frequently with myocarditis; these viruses include influenza virus, Epstein–Barr virus, 
cytomegalovirus, human herpesvirus (Kindermann et al., 2008) and varicella-zoster virus. 
Myocarditis and pericarditis were reported in association with influenza virus infection 
during the 1918–1919 pandemic. Unusually, myocarditis has also been described as a 
complication of mumps in a severe but usually self-limited form. Molecular diagnostic 
assays have implicated mumps virus in some cases of endocardial fibroelastosis following 
myocarditis as well. In more recent study of 172 patients with a biopsy sample showing 
myocarditis, the most common viruses were parvovirus B19, 36.6 percent; enterovirus, 32.6 
percent; co-infection with HHV-6 and parvovirus B19, 12.6 percent human herpesvirus 6 
(HHV-6), 10.5 percent; adenovirus, 8.1 percent (Kuhl et al., 2005).  
The novel influenza virus A (H1N1) pandemic began in Mexico in 2009 and rapidly spread 
worldwide. The cardiac complications of H1N1 infection were uncommonly reported. 
Sudden death as a result of myocarditis was a rare recognized complication in otherwise 
immunocompetent individuals, despite the absence of significant respiratory tract infection. 
A report from Japan described 10 patients presented with fulminant myocarditis which was 
confirmed by endomyocardial biopsy in 6 patients, 8 of the cases were rescued (Ukimura et 
al., 2009). Also, a documented influenza myocarditis was reported due to 2009 pandemic 
H1N1 virus occurred in a previously healthy adult (Haessler et al., 2010). Another reported 
fatal case of acute myocarditis in an immunocompetent young woman, the autopsy revealed 
a predominantly lymphocytic myocarditis (Gdynia et al., 2011). On the other hand, cases 
diagnosed with fulminant myocarditis were described in pediatric population with fatal 
outcomes within a 30-day of presentation (Bratincsák et al., 2010).  
Though viral myocarditis is most often self-limited and without sequelae, fulminant 
condition with arrhythmias, heart failure occurs. Arrhythmias are common and are 
occasionally difficult to manage. Patients with fulminant myocarditis may require 
mechanical cardiopulmonary support or cardiac transplantation, but the majority survived 
and many demonstrate substantial recovery of ventricular function. Patients with 
myocarditis and pulmonary hypertension are at a particularly high risk of death. Deaths 
attributed to heart failure, tachyarrhythmias, and heart block has been reported and it seems 
prudent to monitor the electrocardiogram of patients with arrhythmias, especially during 
the acute illness. In some patients, myocarditis simulates acute myocardial infarction, with 
chest pain, electrocardiographic changes, and elevated serum levels of myocardial enzymes. 
Additionally, viral myocarditis are assumed to be the major causes of chronic dilated 
cardiomyopathy, some cases of myocarditis may recur as well, however the number of cases 
with acute myocarditis that progresses to chronic dilated cardiomyopathy remains 
anonymous.  
7.2 Human immunodeficiency virus (HIV) myocarditis  
The human immunodeficiency virus type I (HIV-1) infection that causes the acquired 
immunodeficiency syndrome (AIDS) has became a worldwide pandemic. It has been 
identified for more than 3 decades, during which time a number of factors may altered the 
nature of cardiac manifestation. Notably, the survival in adult with HIV infection and AIDS 
is prolonged as a result of earlier detection and the use of highly active antiretroviral 
therapy (HAART), (Hoover et al., 1993; Palella et al., 1998). On the other hand, disorders 
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such as hypertension, hyperglycemia, hyperlipidemia, lipodystrophy and coronary artery 
disease appeared to add further comorbidity to HIV infection (Fisher & Lipshultz, 2001; 
Friis-Møller et al., 2007; Tershakovec et al., 2004).  
Human immunodeficiency virus is the most common cardiac pathologic finding at autopsy 
in HIV infected patients with prevalence as high as 70 percent (Anderson et al., 1988; Baroldi 
et al., 1988, Lewis, 1989). Myocarditis identified at autopsy or on endomyocardial biopsy in 
HIV-infected patients is most often nonspecific and manifested as focal, inflammatory 
lymphocytic infiltrates without myocyte necrosis. However, it is uncertain whether the 
myocarditis so frequently observed at autopsy is clinically relevant. 
Myocarditis should be considered in any HIV-infected patient with dyspnea or 
cardiomegaly. It is most often present with signs and symptoms of congestive heart 
failure or asymptomatic left ventricular (LV) dysfunction established by 
echocardiography. Of note, the clinical features of concomitant noncardiac disorders may 
mask cardiac involvement and steer to inaccurate approach, since myocardial 
manifestations due of HIV infection may respond at least transiently to standard therapy. 
A prospective long-term clinical and echocardiographic follow-up study of asymptomatic 
HIV-positive patients showed a mean annual incidence of progression to dilated 
cardiomyopathy of 15.9 cases per 1,000 patients. The exact pathogenesis of myocarditis in 
the AIDS is unclear. Possible direct action of HIV on the myocardial tissue or an 
autoimmune process induced by HIV, possibly in association with other cardiotropic 
viruses. It is difficult to assess the clinical significance of viral infection of the 
myocardium in HIV infected patients. A histologic diagnosis of myocarditis was reported 
in 83 percent of patients with dilated cardiomyopathy. This significant proportion had 
focal, nonspecific lymphocytic myocarditis (Barbaro et al., 1998).  
Dilated cardiomyopathy can be subclinical or may present with overt clinical findings. 
Cardiac involvement is often subclinical as echocardiographic studies have demonstrated 
LV dysfunction in 41 percent of asymptomatic HIV-positive individuals (Corallo et al., 
1988). However, in the primary care setting, AIDS cardiac complications are unusual. One 
autopsy series demonstrated no cardiac disease in 115 consecutive autopsies of patients who 
died of AIDS-related complications (Lewis, 1989). In one series of 416 HIV-positive patients 
from Rwanda without a previous history of cardiovascular disease and not receiving 
HAART reported an echocardiographically evident dilated cardiomyopathy in 17.7 percent 
(Twagirumukiza et al., 2007). The overt clinical involvement is seen in 10 percent of HIV 
patients, and the most common clinically significant finding is a dilated cardiomyopathy 
associated with typical findings of congestive heart failure, namely edema and shortness of 
breath.  
Apart from the clinical manifestation which may be seen as a direct consequence of HIV 
infection, a more likely, as a consequence of possible etiologies related to non-HIV 
cardiotrophic viral infection, postviral autoimmune mechanism, drug toxicity or neoplastic 
infiltration by Kaposi sarcoma or lymphoma.  
Since the introduction of HAART regimens there has been a marked reduction in the 
incidence of myocarditis and opportunistic infections, which has led to a nearly 30 percent 
reduction in HIV-associated cardiomyopathy (Barbaro, 2005). Opportunistic infections 
include bacteria, fungi, protozoa, and viruses are the most frequent cause of morbidity and 
mortality in AIDS which is identified in 10 to 15 percent of cases (Hofman et al., 1993). 
However, symptomatic disease appears to be rare. Toxoplasma gondii is the most 
frequently documented infectious cause of myocarditis associated with AIDS. Myocardial 
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toxoplasmosis described in 1 to 16 percent autopsy series of patients dying of AIDS 
(Anderson et al., 1988; Baroldi et al., 1988; Matturri et al., 1990). Cytomegalovirus is another 
common opportunistic infection in patients with late stage AIDS that can cause myocarditis 
in selected patients (Barbaro et al., 1998; Niedt & Schinella, 1985). Other virus identified 
within the myocardium of HIV-infected or AIDS patients, either at antemortem 
endomyocardial biopsy or from autopsy material, have included Epstein-Barr and coxsackie 
B virus in adults (Barbaro et al., 1998; Dittrich et al., 1988) These viruses may be present as 
either primary infection or as coinfection and can occur with or without associated 
myocarditis and with or without associated LV dysfunction. Other infections like, 
myocardial tuberculosis appears to be rare (Miller-Catchpole et al., 1989). Fungal 
myocarditis is another unusual complication of disseminated infection that is identified 
most often at autopsy. Various fungal organisms identified in the myocardium at autopsy 
with associated myocarditis. Cardiac cryptococcus has been diagnosed in association with 
congestive heart failure and resolved after therapy (Kinney et al., 1989; Lafont et al., 1987; 
Lewis et al., 1985). 
Other possible etiologies of LV dysfunction are drug toxicity from either abuse of illicit 
substances or iatrogenic disease from agents used in the therapy for AIDS. Alcohol, cocaine, 
or heroin may contribute to LV dysfunction in many cases (Brown et al., 1991; Peng et al., 
1989; Soodini & Morgan, 2001). Therapeutic agents implicated as potential cardiac toxins 
include zidovudine (d’Amati et al., 1992; Herskowitz et al., 1992), interleukin-2 (Samlowski 
et al., 1989) and interferon alfa-2 (Deyton et al., 1989; Zimmerman et al., 1994). Neoplastic 
infiltration of the heart by Kaposi sarcoma is frequently seen at autopsy and usually 
associated with widespread disease in the terminal phases of AIDS (Silver et al., 1984). Non-
Hodgkin lymphoma is also observed in this setting and also associated with widespread 
disease (Holladay et al., 1992). 
7.3 Bacterial myocarditis 
Nowadays, myocarditis of infectious etiology caused by non-viral agents is less frequent 
worldwide. Bacterial involvement of the heart is uncommon, but when it does occur, it is 
usually as a complication of endocarditis. Various bacteria include (Corynebacterium 
diphtheriae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus pneumoniae, Salmonella 
spp., Neisseria gonorrhoeae, Leptospira, Borrelia burgdorferi, Treponema pallidum, Brucella, 
Mycobacterium tuberculosis, Actinomyces, Chlamydia spp., Coxiella brunetti, Mycoplasma 
pneumoniae and Rickettsia spp). Bacteria like streptococcal and staphylococcal species and 
Bartonella, Brucella, Leptospira, and Salmonella species can spread to the myocardium as a 
consequence of severe cases of endocarditis. Some forms of bacterial myocarditis will be 
discussed below. 
7.3.1 Diphtheritic myocarditis  
Worldwide, the most common bacterial cause of myocarditis is diphtheria. As early as 1806, 
a relationship between infection (diphtheria) and chronic heart disease was postulated, but 
it was not until the 1970s, with the advent of endomyocardial biopsy, that the diagnosis of 
myocarditis could be established during life. 
The risk of developing cardiac toxicity is proportional to the severity of local infection.  
Corynebacterium diphtheriae produce toxins that inhibit protein synthesis that can cause 
myocarditis and leads to a dilated, flabby, hypocontractile heart. The manifestations of 
www.intechopen.com
 
Myocarditis 
 
18
diphtheritic myocarditis include various dysrhythmias, conduction disturbances, and 
dilated cardiomyopathy. Cardiomegaly and severe congestive heart failure typically appear 
after the first week of illness. However, clinically evident cardiac manifestation like 
dyspnea, decreased heart sounds, gallop rhythm or cardiac dilatation is much less common, 
occurring in 10 to 25 percent of all patients with diphtheria (Morgan et al., 1963).  
Myocarditis occurred in 22 percent of 656 hospitalized patients with diphtheria in the 
Kyrgyz Republic in 1995; 7 percent of patients with myocarditis and 2 percent of patients 
without myocarditis died (Kadirova et al., 2000). Myocarditis as evidenced by 
electrocardiographic changes such as ST-T wave changes, QTc prolongation, and/or first-
degree heart block can be detected in as many as two-thirds of cases, often occurring when 
local respiratory symptoms are improving (Boyer & Weinstein, 1963; Lumio et al., 1948). The 
conduction system is frequently involved. The complete heart block result from diphtheritic 
myocarditis was almost always fatal before temporary cardiac pacemakers were developed. 
Diphtheritic myocarditis considered the most serious complication and remains the major 
cause of mortality (Kneen et al., 2004). The death rate is highest during the first week of 
illness particularly among patients with bull-neck diphtheria and among patients with 
myocarditis who develop ventricular tachycardia, atrial fibrillation, or complete heart block.  
7.3.2 Lyme myocarditis  
Lyme disease is an inflammatory disease caused by infection with the spirochete Borrelia 
burgdorferi. In United States, carditis occurs in approximately 5 percent, while, it is less 
frequent in Europe, affecting approximately 0.3 to 4.0 percent of untreated adults (Cox et al., 
1991). This difference may be related to infection by different organisms. 
A careful history should address risk factors or possible evidence of B. burgdorferi infection 
particularly in the presence of atrioventricular conduction abnormalities (McAlister et al., 
1989). These include history of residence or travel through an endemic area; previous tick 
bites; prior or current erythema migrans lesions and coexistence of objective or subjective 
neurologic dysfunction compatible with neurologic Lyme disease. Cardiac Lyme disease 
occurs during the early disseminated phase of the disease, usually within weeks to a few 
months after infection (Fish, 2008). In a patient with suspected Lyme disease after a tick bite, 
the possibility of coinfection with Ehrlichia (ehrilichiosis) and Babesia (babesiosis) should be 
considered as both can also cause myocarditis. 
There is a male predominance of approximately 3:1 in cardiac Lyme disease (Vlay, 1993). 
Patients with cardiac involvement may be asymptomatic and clinically inapparent.  
However, some patients develop symptomatic myocarditis with cardiac muscle dysfunction 
and/or associated pericarditis (Vlay et al., 1991) (Lorcerie et al., 1987). Symptoms mainly 
include palpitations, shortness of breath, chest pain, presyncope or syncope. In a review of 
84 patients with Lyme carditis, the United States Centers for Disease Control and Prevention 
reported palpitations in 69 percent, conduction abnormalities in 19 percent, myocarditis in 
10 percent and left ventricular failure 5 percent (Ciesielski et al., 1989). Endomyocardial 
biopsy samples resemble idiopathic lymphocytic myocarditis, and rarely the spirochetal 
organisms are identified (Cox et al., 1991; McAlister et al., 1989; Stanek et al., 1990). 
Atrioventricular conduction block of varying degrees are the most common manifestation of 
Lyme carditis. In some patients, heart block is the first and only manifestation of Lyme 
disease (Kimball et al., 1989). Patients may present with first degree heart block but can 
progress to second degree or complete heart block over a short period of time (Peeters et al., 
1990). One review of 52 patients with Lyme carditis found that 87 percent had 
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atrioventricular block, which was usually symptomatic (McAlister et al., 1989). Wenckebach 
periodicity occurred in 40 percent and complete atrioventricular block in 50 percent; other 
findings include bundle branch and fascicular blocks, which are rare. In another report, 38 
percent of patients with Lyme carditis required a temporary pacemaker (Goldings & Jericho, 
1986). Patients with a PR interval greater than 300 milliseconds carry a highest risk for 
progression to complete heart block, which may develop rapidly (Steere et al., 1980). 
Complete heart block caused by Lyme disease typically resolves within one week, and more 
minor conduction disturbances within six weeks (Fish, 2008; McAlister et al., 1989). More 
reports showed heart block usually persists for 3 to 42 days and often resolves 
spontaneously (Costello et al., 2009; Cox et al., 1991; Steere et al., 1980; van der Linde et al., 
1989). In Europe, scattered case reports have suggested that B. burgdorferi may, in isolated 
cases, be a cause of chronic cardiomyopathy (Bartůnek et al., 2006; Palecek et al., 2010). This 
has not been shown in the United States. A small Dutch series evaluated 42 patients with 
dilated cardiomyopathy (Vlay et al., 1991). Nine were seropositive for anti-B. burgdorferi; 
six recovered fully, two had a partial response, and one showed no improvement. 
7.3.3 Salmonella myocarditis 
Typhoid fever is a life-threatening illness rarely complicated by myocarditis. Salmonella 
myocarditis may produce variable clinical manifestations from latent to severe clinical 
forms, such as acute congestive heart failure or sudden cardiac death (Al-Aqeedi et al., 2009; 
Burt et al., 1990). Postmortem studies suggest that myocarditis is a major cause of sudden 
unexpected death in young adults and may account for 20 percent of cases (Feldman & 
McNamara, 2000).  
7.3.4 Yersinia myocarditis 
Myocarditis sometimes occurs as a complication of Yersinia. Clinical evidence of 
Campylobacter-associated myocarditis described in association with Campylobacter spp. 
enteritis (Kotilainen et al., 2006). Mild, self-limited myocarditis accompanies 10 percent of 
cases of Yersinia induced arthritis and can occur independently. Typical manifestations 
include cardiac murmurs and transient electrocardiographic abnormalities, such as 
prolongation of the PR interval and nonspecific ST-segment and T wave changes. The 
syndrome of Yersinia-induced arthritis and carditis can be confused with acute rheumatic 
fever.  
7.3.5 Legionella myocarditis 
Myocardial involvement is a rare manifestation of Legionella infection, though, the most 
common extrapulmonary site of Legionnaires’ disease is the heart. Numerous reports have 
described myocarditis, pericarditis, postcardiotomy syndrome, and prosthetic valve 
endocarditis (Antonarakis et al., 2006; Lowry & Tompkins, 1993; Tompkins et al., 1988). 
Most cases have been hospital acquired. Legionella carditis in the adult population is 
invariably seen in association of pneumonia, however, isolated Legionella myocardial 
involvement without associated pneumonia have been reported (Burke et al., 2009). 
7.3.6 Mycoplasma myocarditis 
Cardiac abnormalities rarely reported in conjunction with Mycoplasma pneumoniae infection 
including myocarditis and pericarditis (Martin & Bates, 1991; Paz & Potasman, 2002). 
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Myocarditis has been described in rare autopsy reports as well. Cardiac manifestations 
include rhythm disturbances, congestive heart failure, chest pain, and conduction 
abnormalities on the electrocardiogram. 
7.3.7 Q fever myocarditis 
Myocarditis, though uncommon, may be a particularly severe manifestation of Q fever. A 
study of 1070 patients with acute Q fever from southern France, 1 percent had pericarditis, 
and 1 percent had myocarditis. In other series of 1276 patients with Q fever over a 15-year 
period, only eight developed myocarditis but two were among only 12 total patients with Q 
fever who died (Fournier et al., 2001). Q fever may also cause endocarditis which usually 
occurs in patients with previous valvular damage or immunocompromise particularly a 
bicuspid aortic valve or a prosthetic valve. 
7.3.8 Chlamydial myocarditis 
Chlamydial infection also has been reported in association with clinical manifestations of 
myocarditis (Mavrogeni et al., 2008).  
7.3.9 Relapsing fever myocarditis 
Relapsing fever is an arthropod-borne infection characterized by recurrent episodes of fever, 
caused by spirochetes of the genus Borrelia. The first episode of illness tends to be the most 
severe. Myocarditis appears to be common in both louse-borne and tick-borne relapsing 
fever. Clinical and electrocardiographic evidence of myocarditis and myocardial 
dysfunction includes a prolonged QTc interval, commonly a galloping third heart sound, 
elevated central venous pressure, arterial hypotension, and rare pulmonary congestion. 
Heart involvement has been prominent in fatal cases (Wengrower et al., 1984).  
7.4 Acute rheumatic fever 
Acute rheumatic fever (ARF) is a nonsuppurative complication of group A streptococcus 
pharyngitis that occurs two to four weeks following infection and arises as an autoimmune 
response to extracellular or somatic bacterial antigens that share similar epitopes in human 
tissue. Rheumatic fever remains one of the most important cardiovascular diseases that 
cause significant cardiac morbidity and mortality in developing countries (Hutchison, 1998). 
In developed countries, ARF is generally preceded by pharyngitis but not skin infection 
(Guidelines for the diagnosis of rheumatic fever, JAMA 1992). However, data from endemic 
regions with ARF and rheumatic heart disease suggest a less clear association (McDonald et 
al., 2004, 2006; Noel et al., 2005). 
Acute rheumatic fever occurs most frequently in children from 5 to 15 years of age. The 
incidence of rheumatic heart disease in patients with a history of ARF is variable; in general, 
valvular damage manifesting as a murmur later in life is likely to occur in about 50 percent 
of patients with evidence of carditis at initial presentation (Albert et al., 1995; Meira et al., 
2005). The myocardial lesions consist of nonspecific lymphocytic myocarditis and Aschoff 
nodules. The latter are pathognomonic of ARF. Myocarditis is often indicated by 
cardiomegaly and/or congestive heart failure (CHF) particularly in the absence of a 
significant pericardial effusion. The presence of valvulitis is established clinically by 
auscultatory findings. Although CHF in rheumatic fever patients traditionally has been 
ascribed to severe myocardial inflammation, endomycardial biopsy in patients with 
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rheumatic carditis does not show significant evidence of myocyte damage (Narula et al., 
1993). In addition, echocardiographic left ventricular ejection fraction and indices of 
myocardial contractility remain normal in patients with rheumatic carditis even in the 
presence of CHF (Essop et al., 1993). Further, CHF occurs only in the presence of 
hemodynamically significant valvular lesions. 
The diagnosis of ARF is established largely on clinical grounds. The clinical manifestations 
initially described by Jones (Jones, 1944). Subsequently revised and lastly the established 
guidelines for the diagnosis of rheumatic fever reviewed by the American Heart Association 
Working Group in 2002 (Ferrieri, 2002). The five major manifestations include migratory 
arthritis, carditis and valvulitis, central nervous system involvement (eg, Sydenham chorea), 
erythema marginatum and subcutaneous nodules. Whereas, the four minor manifestations 
include, arthralgia, fever, elevated acute phase reactants (erythrocyte sedimentation rate, C-
reactive protein) and prolonged PR interval. The probability of ARF is high in the setting of 
group A streptococcal infection followed by two major manifestations or one major and two 
minor manifestations. Strict adherence to the Jones criteria in areas of high prevalence may 
result in under detection of the disease. This was illustrated in a report of 555 cases of 
confirmed ARF among Australian aboriginals in whom monoarthritis and low-grade fever 
were important manifestations (Carapetis & Currie, 2001). 
7.5 Chagas myocarditis 
Chagas disease is a protozoan infection due to Trypanosoma cruzi; transmitted by an insect 
vector, produces an extensive myocarditis that typically becomes evident years after the 
initial infection. It is a major public health problem in endemic areas and in immigrants 
from rural Central or South America. Chagas myocarditis is by far the most common form 
of cardiomyopathy in Latin American countries (Schofield & Dias, 1991). Chagas disease 
consists of acute and chronic phases. During the chronic phase, many patients present the 
indeterminate form. The latter describes patients who have positive serology, but no 
symptoms, physical signs, or laboratory evidence of organ involvement (Dias, 1989).  
7.5.1 Acute phase 
The first signs of acute Chagas’ disease develop at least 1 week after contact with the 
infected vector. Local skin indurated erythema and swelling produces the typical portal of 
entry lesions at the skin known as chagomas accompanied by local lymphadenopathy. The 
conjunctiva portal of entry may result in a unilateral painless periorbital edema and 
swelling of the palpebrae (Romana's sign). Infection can also occur through blood 
transfusion, congenital transmission, and, much less often, organ transplantation, laboratory 
accident, breast feeding, and oral contamination (Benchimol Barbosa, 2006). Although heart 
transplantation for Chagas cardiomyopathy has been successfully performed, reactivation of 
Trypanosoma cruzi is common. These initial local signs may be followed by malaise, fever 
sweating, myalgias anorexia, and a morbilliform rash may also appear. Generalized 
lymphadenopathy and hepatosplenomegaly may develop. Cardiac failure occur secondary 
to myocarditis; cardiac involvement is present in over 90 percent of those in whom the 
diagnosis is made (Pinto et al., 2004). The frequency and severity of myocarditis are 
inversely proportional to age (Dias & Kloetzel, 1968). The acute symptoms resolve 
spontaneously in virtually all patients, who then enter the asymptomatic or indeterminate 
phase of chronic T. cruzi infection. The electrocardiogram normalized in over 90 percent of 
patients after one year. 
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The indeterminate form usually lasts 10 to 30 years and only approximately 30 percent of 
the patients develop overt cardiac disease. Most patients remain asymptomatic throughout 
life. The natural history of this phase of disease is characterized by subtle degree of cardiac 
involvement and gradual appearance of clinical or electrocardiographic markers of cardiac 
involvement, which signals the onset of the chronic phase. In one review, progression from 
indeterminate to the full-blown clinical form in the chronic phase occurred at approximately 
2 percent per year (Dias, 1989). In another report, 38.3 percent of patients with positive 
serology but without symptoms developed chagasic cardiomyopathy over a 10-year period 
(Coura et al., 1985). About 50 percent of patients remain with the indeterminate form 
indefinitely (Marin-Neto et al., 2003). 
7.5.2 Chronic phase 
The chronic form is characterized by dilatation of several cardiac chambers, fibrosis and 
thinning of the ventricular wall, aneurysm formation (especially at the left ventricular apex), 
and mural thrombi.  
Chronic progressive heart failure is the rule and is associated with poor survival. Mortality 
associated with the chronic phase almost exclusively due to cardiovascular involvement. 
The cause of death is sudden cardiac death in 55 to 65 percent, progressive heart failure in 
25 to 30 percent, and stroke in 10 to 15 percent (Rassi et al., 2001). Symptoms and physical 
signs at this stage of the disease arise from three basic syndromes that often coexist in the 
same patient, heart failure, cardiac dysrhythmia, and thromboembolism (systemic and 
pulmonary). Heart failure in Chagas heart disease is usually biventricular and commonly 
presented with fatigue. However, right-sided failure manifested with increased jugular 
venous pressure, peripheral edema, ascites, and hepatomegaly is characteristically more 
pronounced than those of left-sided failure manifested with dyspnea and pulmonary rales. 
Both systolic and diastolic dysfunction can occur (Sousa et al., 1988). Cardiac examination 
typically reveals the findings of murmurs of mitral and tricuspid regurgitation, wide 
splitting of the second heart sound due to right bundle branch block and prominent diffuse 
apical thrust.  
Cardiac arrhythmias may cause palpitation, lightheadedness, dizziness, or syncope. 
Autonomic dysfunction results in marked abnormalities in the heart rate changes. Chest 
pain is common symptom and usually atypical in Chagas heart disease. It may mimic 
angina due to abnormal coronary vasomotion postulated as underlying mechanism (Marin-
Neto et al., 1992). Sudden cardiac death accounts for 55 to 65 percent of deaths in CD; the 
real frequency of this complication is probably underestimated, particularly in rural areas 
(Rassi et al., 2001). Sudden cardiac arrest can occur even in previously asymptomatic 
patients (Rassi Júnior et al., 1995). However, most patients have severe underlying heart 
disease, including ventricular aneurysms at multiple sites (posterior-lateral, inferior basal, or 
apical), which is a characteristic finding in Chagas heart disease (Rassi Júnior et al., 1995). 
Sudden death is usually precipitated by exercise, and can be caused by VT or fibrillation, 
asystole, or complete AV block (Mendoza et al., 1986). The electrocardiogram is abnormal in 
most patients with cardiac involvement and typically shows right bundle branch block, left 
anterior hemiblock and diffuse ST-T changes, which may progress to complete 
atrioventricular block.Ventricular arrhythmia may also be seen in form of premature beats 
that may be multiform and runs of nonsustained ventricular tachycardia. The severity of 
ventricular arrhythmias tends to correlate with the degree of LV dysfunction. Other changes 
like, abnormal Q waves, various degrees of atrioventricular block, QT interval prolongation 
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and variation in the QT interval (QT dispersion) are frequent findings (Salles et al., 
2003).Virtually all types of atrial and ventricular arrhythmias occur frequently, atrial 
fibrillation and low QRS voltage may be observed in advanced disease. 
A potentially serious complication of chronic Chagas heart disease is thromboembolism. In 
a review of 1345 autopsies, cardiac thrombus or thromboemboli reported in 44 percent; both 
right and left cardiac chambers equally affected (Samuel et al., 1983). Although 
thromboembolic phenomena were more common in the systemic circulation, pulmonary 
embolism accounted for 14 percent of deaths. Cardioembolism appears to be an important 
cause of acute ischemic stroke. One series of 94 patients with Chagas disease in Brazil 
reported higher rate of cardioembolism (56 versus 9 percent) as compared to control group 
(Carod-Artal et al., 2005). Stroke was also reported significantly more frequent in patients 
who had Chagas disease related cardiomyopathy compared with patients who had other 
cardiomyopathies (15.0 versus 6.3 percent), (Oliveira-Filho et al., 2005). Echocardiography or 
contrast ventriculography may reveal a left ventricular apical aneurysm, regional wall 
motion abnormalities,or diffuse cardiomyopathy. The cause of death is either intractable 
CHF or an arrhythmia, with a minority of patients dying from embolic phenomena. 
7.6 Fungal myocarditis 
The incidence of invasive fungal disease has dramatically increased over the past few 
decades corresponding to the rising number of immunocompromised patients. Cardiac 
fungal infection, especially myocarditis, may be difficult to recognize clinically and may in 
itself produce a fatal outcome. Myocardial involvement frequently occurs in disseminated 
fungal infection in which multiple organs often affected. Conditions that appear 
predisposing to fungal infection are human immunodeficiency virus infection, medication 
like, corticosteroids, antineoplastic agents or broad-spectrum antibiotics, alone or in 
combination with invasive medical procedures (Nosanchuk, 2002). Candida was the most 
frequently observed organism, while Aspergillus was the second most frequent fungus to 
involve the heart. Rarely Cryptococcus identified as a cause of myocarditis as well. 
7.7 Eosinophilic and hypersensitivity myocarditis 
The association between eosinophilia (eosinophil count >500/mm3) and heart disease was 
first identified by Loeffler (Loeffler, 1936). A specific eosinophilic form of myocarditis 
identified following drug-induced hypersensitivity reactions and systemic 
hypereosinophilic syndromes (Taliercio et al., 1985).  
Eosinophilic myocarditis is characterized by a predominantly mature eosinophils infiltration 
of the myocardium and other organ systems. It occurs in association with systemic diseases 
such as hypereosinophilic syndrome, Churg-Strauss syndrome and Löffler’s 
endomyocardial fibrosis. Also it may occur in association with cancer, parasitic, helminthic 
or protozoal infections such as Chagas disease, toxoplasmosis, schistosomiasis, trichinosis, 
hyatid cysts and visceral larval migrans (Corradi et al., 2004; Corssmit et al., 1999; Spodick, 
1997). Eosinophilic myocarditis has been reported after vaccination for several diseases, 
including smallpox (Arness et al., 2004; Barton et al., 2008). Acute eosinophilic necrotizing 
myocarditis is a rare aggressive form of eosinophilic myocarditis and may represent an 
extreme form of hypersensitivity myocarditis which characterized by acute onset and 
rapidly results in cardiovascular deterioration and circulatory collapse carried high 
mortality rates (Cooper & Zehr, 2005). The clinical manifestations of eosinophilic 
myocarditis may include right and left congestive heart failure, endocardial and valvular 
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fibrosis leading to regurgitation, and formation of endocardial thrombi. Clinical awareness 
warranted when presentation may mimics acute myocardial infarction, with ischemic chest 
pain and ST-segment elevation on electrocardiography (Galiuto et al., 1997). 
Hypersensitivity myocarditis is a form of eosinophilic myocarditis due to autoimmune 
reaction affecting the heart muscle, often induced by drug. It is often first discovered at 
postmortem examination. In one series, the prevalence of clinically undetected 
hypersensitivity myocarditis in explanted hearts ranged from 2.4 to 7 percent (Wu et al., 
2002). 
Numerous drugs have been implicated in hypersensitivity myocarditis including, antibiotics 
(Burke et al., 1991) like penicillins, cephalosporins and sulfonamides; antipsychotics (Killian 
et al., 1999) like clozapine and tricyclic antidepressants (Ansari et al., 2003; Burke et al., 1991; 
Kounis et al., 1989); others like methyldopa, hydrochlorothiazide, furosemide, tetracycline, 
azithromycin, aminophylline, phenytoin and benzodiazepines (Ben m'rad et al., 2009; 
Pursnani et al., 2009; Taliercio et al., 1985). Hypersensitivity myocarditis not constantly 
develop early in the course of medication. Patients taking the antipsychotic agent clozapine 
have been reported to develop myocarditis more than two years after the drug was started 
(Haas et al., 2007). Prolonged continuous infusion of dobutamine has also been associated 
with hypersensitivity myocarditis which has been reported in 2.4 to 23 percent (Spear, 1995; 
Takkenberg et al., 2004). Cocaine also rarely produce a hypersensitivity myocarditis, unlike 
the hypereosinophilic syndrome, peripheral eosinophilia is typically absent (Isner & 
Chokshi, 1991). 
Clinically, the presentation often heralded by fever, peripheral eosinophilia and a drug rash 
that occurs days to weeks after administration of a previously well-tolerated agent.  
Electrocardiographic abnormalities show nonspecific ST segment changes or infarct patterns 
(Fenoglio et al., 1981). Myocardial involvement varies but usually does not result in 
fulminant heart failure or hemodynamic collapse. However, some patients present with 
sudden death or rapidly progressive heart failure (Burke et al., 1991; Galiuto et al., 1997). 
Eosinophilic myocarditis can be a manifestation of eosinophilia-myalgia syndrome, which is 
a multisystem disease caused by ingestion of contaminants in L-tryptophan containing 
products (Belongia et al., 1990), characterized by peripheral eosinophilia and generalized 
disabling myalgias (Martin et al., 1990). Eosinophils, lymphocytes, macrophages, and 
fibroblasts accumulate in the affected tissues, but their role in pathogenesis is unclear. The 
disease is frequently evolves into a chronic course but can be fatal in up to 5% of patients.  
7.8 Giant cell myocarditis 
Idiopathic giant cell myocarditis is a rare inflammatory disease that often affects previously 
healthy young adults and frequently fatal type of myocarditis (Cooper et al., 2008). The 
pathogenesis of this disorder is not known. It is identified by the presence of multinucleated 
giant cells associated with eosinophils and myocyte destruction in the absence of 
granulomas on endomyocardial biopsy. It is thought to be primarily autoimmune in nature 
because of the reported comorbidity with a variety of autoimmune disorders (Cooper et al., 
1997), thymoma, (Kilgallen et al., 1998) and drug hypersensitivity (Daniels et al., 2000). 
Idiopathic giant cell myocarditis is usually a fulminant form of myocarditis and 
characterised by a history of rapid progression of severe heart failure associated with 
refractory sustained ventricular arrhythmias. Giant-cell myocarditis is sometimes 
distinguished from the much more common postviral myocarditis by the presence of 
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ventricular tachycardia, heart block, and a downhill clinical course, despite optimal clinical 
care. In the series of 63 patients with giant cell myocarditis enrolled in the multicenter Giant 
Cell Myocarditis Treatment Trial, 75 percent identified with heart failure symptoms as the 
primary presentation, 14 percent with ventricular arrhythmia and heart block in 5 percent 
(Cooper et al., 1997). Most patients will require cardiac transplantation, the median survival 
from the onset of symptoms of less than 6 months and has an 89 percent rate of death or 
transplantation. This represents a significantly worse outcome compared to lymphocytic or 
viral myocarditis. Despite a 25 percent incidence of post-transplantation recurrence of giant 
cell myocarditis detected by biopsy, the 5-year survival after transplantation is about 71 
percent which is comparable to survival after transplantation for cardiomyopathy. 
7.9 Systemic lupus erythematosus myocarditis 
Acute myocarditis is an uncommon manifestation of systemic lupus erythematosus (SLE), 
with a prevalence of 8 to 25 percent in different studies (Apte et al., 2008; Mandell, 1987). 
Myocarditis frequently asymptomatic but less often may accompany other manifestations of 
acute SLE. In particular pericarditis, commonly occur in about two-thirds of patients, and 
generally follows a benign course, however tamponade or constriction may occur 
infrequently. 
Myocarditis generally parallels the activity of the disease and, although common 
histologically, rarely results in clinical heart failure unless associated with hypertension. 
African American ethnicity is associated with a higher risk of myocarditis compared with 
Hispanic and Caucasian ethnicity (Apte et al., 2008). Myocarditis should be suspected if 
there is resting tachycardia disproportionate to body temperature, ST and T wave 
electrocardiographic abnormalities and unexplained cardiomegaly. The cardiomegaly may 
be associated with symptoms and signs of heart failure, conduction abnormalities or 
arrhythmias (Moder et al., 1999). Patients with SLE are at increased risk for myocardial 
ischemia due to accelerated atherosclerosis or coronary arteritis. Endocardial involvement 
with fibrinous endocarditis (Libman & Sachs, 1924) is another serious manifestation can lead 
to valvular insufficiencies or embolic events. Likewise patients with the antiphospholipid 
syndrome have a higher incidence of valvular disease, a variety of thrombotic disorders, 
myocardial infarction, pulmonary hypertension, and cardiomyopathy. Myocardial biopsy 
reveal mononuclear cells infiltration distinguish active myocarditis from fibrosis and other 
causes of cardiomyopathy (Schattner & Liang, 2003) or rarely cardiotoxicity induced by 
hydroxychloroquine (Keating et al., 2005). Inflammation may lead to fibrosis that may be 
manifested clinically as dilated cardiomyopathy. 
7.10 Sarcoid myocarditis 
It is a granulomatous form of myocarditis. The clinical evidence of myocardial involvement 
is present in approximately 5 percent of patients with sarcoidosis. However, an autopsy 
series have reported higher rates of about 25 percent of subclinical cardiac involvement 
(Chapelon-Abric et al., 2004; Kim et al., 2009; Thomsen & Eriksson et al., 1999). The clinical 
manifestations of cardiac sarcoidosis are largely nonspecific and may precede, follow, or 
occur concurrently with involvement of other organs. Sarcoid heart disease should be 
considered in the evaluation of an otherwise healthy young or middle aged person with 
cardiac symptoms or in a patient with known sarcoidosis who develops arrhythmias, 
conduction disease, or heart failure. Patients who present with apparently chronic dilated 
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cardiomyopathy yet with new ventricular arrhythmias or second-degree or third degree 
heart block or who do not have a response to optimal care are more likely to have cardiac 
sarcoidosis (Yazaki et al., 1998). Cardiac symptoms were reported in 101 patients, when 
cardiac sarcoidosis was diagnosed in 84 percent compared to 4 percent in asymptomatic 
patients (Smedema et al., 2005). Endomyocardial biopsy shows characteristic noncaseating 
granulomas. However, the diagnosis can also be inferred if there is a tissue diagnosis of 
sarcoidosis from an extracardiac source in the presence of a cardiomyopathy of unknown 
origin. 
The electrocardiographic abnormalities found in nearly 70 percent of patients with 
sarcoidosis (Chapelon-Abric et al., 2004). Cardiac involvement with sarcoidosis may 
produce clinical symptoms and electrocardiographic findings simulating myocardial 
infarction. Conduction abnormalities in form of first-degree heart block due to disease of the 
atrioventricular node or bundle of His, and various types of intraventricular conduction 
defects, are common among patients with cardiac sarcoidosis (Chapelon-Abric et al., 2004). 
These lesions may initially be silent, but can progress to complete heart block and cause 
syncope (Yoshida et al., 1997). Sustained or nonsustained ventricular tachycardia and 
ventricular premature beats are the second most common presentation of cardiac 
sarcoidosis; electrocardiography reveals ventricular arrhythmias in as many as 22 percent of 
patients with sarcoidosis (Sekiguchi et al., 1980). Supraventricular arrhythmias are 
infrequent. Sudden death due to ventricular tachyarrhythmias or conduction block accounts 
for 25 to 65 percent of deaths due to cardiac sarcoidosis, however, sudden death can occur in 
the absence of a previous cardiac event (Reuhl et al., 1997; Soejima & Yada, 2009; Yazaki et 
al., 2001). Both systolic and diastolic heart failure can occur. Left ventricular aneurysms 
develop in patients with extensive involvement of the myocardium. Mitral incompetence 
may occur with cardiac sarcoidosis due to associated systolic dysfunction and left 
ventricular dilation or due to papillary muscle involvement by sarcoid granulomas (Sato et 
al., 2008). Tricuspid regurgitation with atrioventricular block secondary to infiltration of 
tricuspid valves and conduction system by sarcoid granulomas has been reported as well 
(Goyal & Aragam, 2006). A left atrial granulomatous mass resembling myxoma has been 
reported too (Abrishami et al., 2004). 
7.11 Peripartum cardiomyopathy 
The syndrome is a rare disorder of pregnancy. It was recognized in 1937, as a distinct 
clinical entity (Gouley et al., 1937). Currently, the etiology of peripartum cardiomyopathy 
(PPCM) remains unclear. However, there is compelling data from animal and human 
studies suggesting that PPCM is actually a type of myocarditis arising from an infectious, 
autoimmune, or idiopathic etiology. The relationship between pregnancy and viral 
myocarditis was first published in 1968 (Farber & Glasgow, 1970). Endomyocardial biopsies 
in women with PPCM have demonstrated myocarditis in many patients. The highest 
incidence of myocarditis reported in PPCM was 76 percent (Midei et al., 1990), however 
much lower incidence was reported (8.8 percent), which found to be comparable to an age 
and sex matched control population undergoing transplantation for idiopathic dilated 
cardiomyopathy (9.1 percent), (Rizeq et al., 1994). Viral genomes of parvovirus B19, human 
herpes virus 6, Epstein–Barr virus, and human cytomegalovirus revealed in endomyocardial 
biopsy specimens from patients with PPCM (Bultmann et al., 2005). Other reported data 
linked with Chlamydial infection (Cenac et al., 2003). 
www.intechopen.com
 
Clinical Presentation 
 
27 
Women present with heart failure during the peripartum period and become manifested in 
the last month of pregnancy or within 5 months of the delivery without apparent etiology 
for the heart failure can be found. The clinical scenario is challenging because many normal 
women in the last month of a normal pregnancy experience dyspnea, fatigue and pedal 
edema, symptoms can mimic early congestive cardiac failure. Physical examination can be 
significant for signs of right and left heart failure. Symptoms and signs that should raise the 
suspicion of heart failure include paroxysmal nocturnal dyspnea, chest pain, nocturnal 
cough, new regurgitant murmurs, pulmonary crackles, elevated jugular venous pressure 
and hepatomegaly. The electrocardiogram usually demonstrates a normal sinus or sinus 
tachycardia rhythm, but frequent ectopy and other atrial arrhythmias may also be present. 
Left ventricular hypertrophy, inverted T waves, Q waves, and nonspecific ST-T changes 
have also been reported (Brown & Bertolet, 1998). Recurrence in a subsequent pregnancy 
has been reported. However, significant improvement occurs in up to 50 percent of affected 
women; others are left with a progressive dilated cardiomyopathy.  
8. Conclusion 
The clinical signs and symptoms of myocarditis are highly variable. A thorough medical 
history with emphasis on possible causes is essential. A scrupulous awareness to ample 
clinical scenarios is essential for clinicians, particularly when the cases are lacking apparent 
etiologies or the presentations being similar to acute myocardial infarction, asymptomatic 
left ventricular systolic dysfunction, unexplained ventricular tachyarrhythmias or 
cardiogenic shock. Clinician need to be attentive when evidence of myocardial damage not 
attributable to epicardial coronary artery disease, primary valvular disease or 
noninflammatory causes. Usually, most cases of myocarditis are self limited and a 
spontaneous improvement occurs in a substantial number of patients with lymphocytic 
disease but is rarely, if ever, observed with granulomatous myocarditis. While routine 
diagnostic endomyocardial biopsy is not required in most cases of suspected acute 
myocarditis, the need for biopsy will depend upon the time course and severity of the 
clinical presentation. 
Better understanding of the clinicopathologic aberration that characterize the diverse clinical 
scenarios and more comprehensive understanding of the natural history of the various 
subtypes of myocarditis should assist clinicians for better approach and subsequently plan 
more effective therapy in the future. 
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